Last reviewed · How we verify

NCT06143462

Vestibular Rehabilitation for Unsteadiness After Intratympanic Gentamicin in Patients With Meniere's Disease

Status unknown NA Last updated 22 November 2023
What this trial tests

NA trial testing Usual care in Vestibular Disorder in 48 participants. Status unknown.

Timeline
1 January 2024
Primary endpoint
30 June 2024
31 December 2024

Quick facts

Lead sponsorEye & ENT Hospital of Fudan University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment48
Start date1 January 2024
Primary completion30 June 2024
Estimated completion31 December 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Eye & ENT Hospital of Fudan University

Who can join

Adults 18 to 75, any sex, with Vestibular Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the efficacy of vestibular rehabilitation treatment on unsteadiness after intratympanic gentamicin in patients with Meniere's disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effect of vestibular rehabilitation treatment (VRT) on patients with unsteadiness after intratympanic gentamicin in Menière's disease: protocol for a randomised controlled trial.
    Tong Q, Zhou Y, Wu P, Yu H. · · 2025 · PMID 39987011 · DOI 10.1136/bmjopen-2024-088722

Verify or expand the search:

Other trials of Usual care

Trials testing the same drug.

Other recruiting trials for Vestibular Disorder

Currently open trials in the same condition.

Other Eye & ENT Hospital of Fudan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06143462.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing